西妥昔单抗与5-氟尿嘧啶加顺铂化疗治疗中晚期食管癌患者的临床效果

Clinical efficacy of Cetuximab and 5-fluorouracil plus Cisplatin in the treatment of advanced esophageal cancer

目的探讨西妥昔单抗与5-氟尿嘧啶加顺铂化疗对中晚期食管癌患者的临床治疗效果。方法选取2018年1月至2021年9月广东省江门市新会区人民医院肿瘤防治中心收治的54例中晚期食管癌患者作为研究对象,采用随机数字表法将其分为对照组(27例)和观察组(27例),对照组患者采用5-氟尿嘧啶加顺铂化疗方案,观察组患者则在对照组的基础上增加西妥昔单抗治疗,比较两组患者的临床治疗总有效率、癌胚抗原(CEA)和鳞状细胞癌抗原(SCC)的水平及不良反应发生率。结果两组患者的临床治疗总有效率比较,差异无统计学意义(P>0.05)。治疗后,观察组的CEA和SCC水平均低于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论对于中晚期食管癌患者而言,西妥昔单抗与5-氟尿嘧啶加顺铂化疗的治疗效果较好,能明显降低患者的血清肿瘤标准水平,且不会增加患者的不良反应,值得临床进一步推广。

Objective To investigate the clinical efficacy of Cetuximab and 5-fluorouracil plus Cisplatin in the treatment of patients with advanced esophageal cancer.Methods A total of 54 patients with advanced esophageal cancer admitted to the Cancer Prevention and Treatment Center of Xinhui District People's Hospital from January 2018 to September 2021 were selected as research objects,they were divided into control group(n=27)and observation group(n=27)according to random number table method.The control group received 5-fluorouracil plus Cisplatin chemotherapy.Observation group was additionally added Cetuximab on the basis of control group,and the total clinical response rate,levels of carcinoembryonic antigen(CEA)and squamous cell carcinoma antigen(SCC)and incidence of adverse reactions were compared between the two groups.Results There was no statistical significance in the total effective rate of two groups(P>0.05).After treatment,CEA and SCC levels in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There were no statistical significances in the incidences of adverse reactions between two groups(P>0.05).Conclusion Cetuximab combined with 5-fluorouracil plus Cisplatin has good therapeutic effect on patients with advanced esophageal cancer,which can significantly reduce the serum tumor standard level without increasing the adverse reactions of patients,and is worthy of further clinical promotion.